Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Expected to Rise, TD Cowen Analyst Says

Arcutis Biotherapeutics (NASDAQ:ARQT) had its price target upped by equities researchers at TD Cowen from $30.00 to $35.00 in a research report issued on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock. TD Cowen’s price objective indicates a potential upside of 29.77% from the stock’s current price.

Other analysts have also recently issued reports about the stock. Zacks Research cut shares of Arcutis Biotherapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, December 29th. Needham & Company LLC raised their price objective on Arcutis Biotherapeutics from $31.00 to $36.00 and gave the stock a “buy” rating in a research note on Thursday. Wall Street Zen lowered Arcutis Biotherapeutics from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 14th. The Goldman Sachs Group upped their target price on Arcutis Biotherapeutics from $19.00 to $29.00 and gave the company a “neutral” rating in a report on Thursday, October 30th. Finally, Mizuho lifted their price target on Arcutis Biotherapeutics from $32.00 to $37.00 and gave the stock an “outperform” rating in a research note on Friday, November 28th. Six research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Arcutis Biotherapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $32.14.

Arcutis Biotherapeutics Trading Down 5.6%

Shares of ARQT stock opened at $26.97 on Thursday. The stock has a 50-day simple moving average of $27.24 and a 200 day simple moving average of $23.80. The stock has a market capitalization of $3.35 billion, a P/E ratio of -192.63 and a beta of 1.70. Arcutis Biotherapeutics has a fifty-two week low of $11.86 and a fifty-two week high of $31.77. The company has a quick ratio of 3.28, a current ratio of 3.50 and a debt-to-equity ratio of 0.68.

Arcutis Biotherapeutics (NASDAQ:ARQT) last issued its quarterly earnings results on Wednesday, February 25th. The company reported $0.13 earnings per share for the quarter, beating analysts’ consensus estimates of $0.03 by $0.10. The company had revenue of $129.50 million during the quarter, compared to the consensus estimate of $110.79 million. Arcutis Biotherapeutics had a negative net margin of 4.29% and a negative return on equity of 11.01%. On average, sell-side analysts expect that Arcutis Biotherapeutics will post -1.33 earnings per share for the current fiscal year.

Insider Activity

In other Arcutis Biotherapeutics news, Director Howard G. Welgus sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $25.05, for a total value of $250,500.00. Following the completion of the sale, the director directly owned 59,744 shares of the company’s stock, valued at $1,496,587.20. The trade was a 14.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Patrick Burnett sold 9,794 shares of the stock in a transaction on Wednesday, February 4th. The stock was sold at an average price of $25.81, for a total transaction of $252,783.14. Following the transaction, the insider directly owned 80,651 shares in the company, valued at $2,081,602.31. The trade was a 10.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 124,656 shares of company stock valued at $3,312,365. 9.40% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Arcutis Biotherapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Focus Partners Wealth boosted its holdings in shares of Arcutis Biotherapeutics by 0.8% during the 3rd quarter. Focus Partners Wealth now owns 65,196 shares of the company’s stock worth $1,237,000 after buying an additional 490 shares during the period. Arizona State Retirement System lifted its position in Arcutis Biotherapeutics by 1.8% during the 3rd quarter. Arizona State Retirement System now owns 31,685 shares of the company’s stock worth $597,000 after acquiring an additional 568 shares during the last quarter. Schroder Investment Management Group boosted its holdings in Arcutis Biotherapeutics by 1.1% during the fourth quarter. Schroder Investment Management Group now owns 57,136 shares of the company’s stock valued at $1,604,000 after acquiring an additional 594 shares during the period. AlphaQuest LLC grew its position in shares of Arcutis Biotherapeutics by 5.7% in the third quarter. AlphaQuest LLC now owns 12,603 shares of the company’s stock valued at $238,000 after purchasing an additional 682 shares during the last quarter. Finally, EverSource Wealth Advisors LLC increased its stake in shares of Arcutis Biotherapeutics by 124.0% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,261 shares of the company’s stock worth $37,000 after purchasing an additional 698 shares during the period.

Key Arcutis Biotherapeutics News

Here are the key news stories impacting Arcutis Biotherapeutics this week:

• Positive Sentiment: Solid Q4 results and revenue beat — Arcutis reported a robust Q4 with revenue growth and a GAAP EPS beat, driven by Zoryve adoption; the quarter and raised guidance underpin the bullish view on commercial execution. Arcutis Biotherapeutics surges on earnings beat, raised guidance
• Positive Sentiment: Multiple analyst price-target increases — Needham, TD Cowen and Guggenheim raised targets (to the mid-$30s) and maintain buy ratings, signaling analyst confidence in growth and creating upside narrative for the stock. Benzinga coverage of analyst price-target changes
• Positive Sentiment: Bull case coverage highlights pipeline and label-expansion catalysts — Recent analyst and media pieces emphasize Zoryve market leadership, operating leverage and upcoming pediatric/label catalysts that could support longer-term upside. Arcutis Earnings: Zoryve Dominance And Pipeline Catalysts Drive The Bull Case
• Neutral Sentiment: Investor presentation scheduled — Management will present at TD Cowen’s healthcare conference next week, giving investors an opportunity for updated guidance/visibility; this is a near-term catalyst but not an immediate earnings event. Arcutis Management to Present at TD Cowen’s 46th Annual Health Care Conference
• Neutral Sentiment: Broad coverage and transcripts available — Earnings call transcript and multiple recaps give investors transparency into execution and guidance; this helps short- and long-term assessment but is informational. Arcutis (ARQT) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Near-term EPS cuts by HC Wainwright — Despite maintaining a Buy and $34 target, HC Wainwright lowered Q2–Q4 2026 EPS estimates, which can temper short-term sentiment and provide a rationale for profit-taking after the post-earnings rally.
• Negative Sentiment: Mixed/unclear short-interest data — Recent short-interest reports appear inconsistent (zero/NaN entries), creating uncertainty about downside pressure from traders; unclear short-covering dynamics can add volatility.

About Arcutis Biotherapeutics

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

In August 2022, Arcutis received U.S.